Gamida Cell Ltd. (GMDA)

NASDAQ: GMDA · IEX Real-Time Price · USD
1.48
+0.16 (12.12%)
At close: Mar 21, 2023, 4:00 PM
1.49
+0.01 (0.68%)
After-hours: Mar 21, 2023, 7:44 PM EDT
12.12%
Market Cap 110.38M
Revenue (ttm) n/a
Net Income (ttm) -87.41M
Shares Out 74.58M
EPS (ttm) -1.28
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 1,136,408
Open 1.36
Previous Close 1.32
Day's Range 1.33 - 1.53
52-Week Range 1.10 - 4.72
Beta 1.66
Analysts Buy
Price Target 12.65 (+754.73%)
Earnings Date Mar 27, 2023

About GMDA

Gamida Cell Ltd., a clinical-stage biopharmaceutical company, develops cell therapies to cure blood cancers and serious hematologic diseases. The company's lead product candidate is omidubicel, a cell therapy that has completed Phase III clinical trial in patients with high-risk hematologic malignancies, as well as in Phase I/II clinical trials in patients with severe aplastic anemia. It is also developing GDA-201, a natural killer cell-based cancer immunotherapy, which is in Phase I/II studies for the treatment of relapsed or refractory non-Ho... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Oct 26, 2018
Employees 166
Stock Exchange NASDAQ
Ticker Symbol GMDA
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 11 analysts, the average rating for GMDA stock is "Buy." The 12-month stock price forecast is $12.65, which is an increase of 754.73% from the latest price.

Price Target
$12.65
(754.73% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Gamida Cell Announces Changes to Board of Directors

BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), a cell therapy pioneer working to turn cells into powerful therapeutics, today announced the resignation of Chairman Robert I. Blum. The Board...

1 day ago - Business Wire

Gamida Cell Announces the Date of Its Fourth Quarter and Full Year 2022 Financial Results and Webcast

BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), a cell therapy pioneer working to turn cells into powerful therapeutics, today announced that the company will host a conference call and live...

1 day ago - Business Wire

Gamida Cell to Present Corporate Highlights at the Oppenheimer 33rd Annual Healthcare Conference

BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), a cell therapy pioneer working to turn cells into powerful therapeutics, today announced that Abbey Jenkins, President and Chief Executive Off...

2 weeks ago - Business Wire

Data Presented on Gamida Cell's Omidubicel, GDA-201 at the 2023 Tandem Meetings of ASTCT and CIBMTR

BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd.

1 month ago - Business Wire

Gamida Cell (GMDA) Upgraded to Buy: Here's Why

Gamida Cell (GMDA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

2 months ago - Zacks Investment Research

Gamida Cell Announces Closing of $25 Million Financing With Highbridge

BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), the global leader in the development of NAM-enabled cell therapies for patients with hematologic and solid cancers and other serious disease...

3 months ago - Business Wire

Gamida Cell to Present Corporate Highlights at Multiple Upcoming Investor Conferences

BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), the leader in the development of NAM-enabled cell therapies for patients with hematologic and solid cancers and other serious diseases, toda...

4 months ago - Business Wire

Gamida Cell Provides Regulatory Update on Omidubicel

BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), the leader in the development of NAM-enabled cell therapies for patients with hematological and solid cancers and other serious diseases, to...

4 months ago - Business Wire

Gamida Cell Reports Third Quarter 2022 Financial Results and Provides Company Update

BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), the leader in the development of NAM-enabled cell therapies for patients with hematologic and solid cancers and other serious diseases, toda...

4 months ago - Business Wire

Gamida Cell to Present Corporate Highlights at the Jefferies London Healthcare Conference

BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd.

4 months ago - Business Wire

Gamida Cell Announces the Date of Its Third Quarter 2022 Financial Results and Webcast

BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd.

4 months ago - Business Wire

GDA-501, NAM enabled NK Cell Therapy, Demonstrates Promising Antitumor Activity Against HER2+ Cancers

BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd.

4 months ago - Business Wire

Gamida Cell Announces Omidubicel Data To Be Presented as an Oral Presentation at 64th ASH Annual Meeting

BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd.

4 months ago - Business Wire

Gamida Cell to Present Corporate Highlights at 2022 Cell & Gene Meeting on the Mesa

BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), the leader in the development of NAM-enabled cell therapy candidates for patients with hematologic and solid cancers and other serious disease...

5 months ago - Business Wire

Long-Term Data from Omidubicel Phase 3 Trial Demonstrates Overall Survival and Sustainable Durable Outcomes for Patients with Blood Cancers at the Society of Hematologic Oncology Meeting

BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), the leader in the development of NAM-enabled cell therapies for patients with hematologic and solid cancers and other serious diseases, today ...

6 months ago - Business Wire

Gamida Cell Announces Pricing of Approximately $20 Million Public Offering of Ordinary Shares

BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), the global leader in the development of NAM-enabled cell therapies for patients with hematologic and solid cancers and other serious diseases,...

6 months ago - Business Wire

Gamida Cell Announces Entry into Commitment Letter with Highbridge for $25 Million Financing

BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), the global leader in the development of NAM-enabled cell therapies for patients with hematologic and solid cancers and other serious diseases,...

6 months ago - Business Wire

Gamida Cell Announces Launch of Public Offering of Ordinary Shares

BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), the global leader in the development of NAM-enabled cell therapies for patients with hematologic and solid cancers and other serious diseases,...

6 months ago - Business Wire

Gamida Cell Appoints Abigail L. Jenkins as President and Chief Executive Officer, Bringing Broad Leadership Experience in Commercializing Innovative Therapies

BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), the global leader in the development of NAM-enabled cell therapies for patients with hematologic and solid cancers and other serious diseases,...

6 months ago - Business Wire

Gamida Cell Presents Data Demonstrating the Impact of Transplantation with Omidubicel for Patients with Hematologic Malignancies at 2022 Cord Blood Connect Meeting

BOSTON--(BUSINESS WIRE)-- #BloodCancerAwarenessMonth--Gamida Cell Ltd. (Nasdaq: GMDA), the leader in the development of NAM-enabled cell therapies for patients with hematologic and solid cancers and o...

6 months ago - Business Wire

Gamida Cell Reports Second Quarter 2022 Financial Results and Provides Company Update

BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), the leader in the development of NAM-enabled cell therapies for patients with hematologic and solid cancers and other serious diseases, today ...

7 months ago - Business Wire

Gamida Cell Announces Dosing of First Patient in Company-Sponsored Phase 1/2 Study of NK Cell Therapy Candidate GDA-201

BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), the leader in the development of NAM-enabled cell therapy candidates for patients with hematologic and solid cancers and other serious disease...

7 months ago - Business Wire

Gamida Cell Announces the Date of Its Second Quarter 2022 Financial Results and Webcast

BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), the leader in the development of NAM-enabled cell therapy candidates for patients with hematologic and solid cancers and other serious disease...

8 months ago - Business Wire

Gamida Cell Announces FDA Acceptance of Biologics License Application for Omidubicel with Priority Review

BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), the leader in the development of NAM-enabled cell therapy candidates for patients with hematologic and solid cancers and other serious disease...

8 months ago - Business Wire

Gamida Cell to Present Corporate Highlights at the JMP Securities Life Sciences Conference

BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), the leader in the development of NAM-enabled cell therapy candidates for patients with hematologic and solid cancers and other serious disease...

10 months ago - Business Wire